The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
Open accessAbstract
Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms (including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon according to large multinational cohorts, including against isolates resistant to carbapenems, ceftazidime/avibactam, ceftolozane/tazobactam, and colistin. However, alarming proportions of resistance have been reported in some recent cohorts (up to 50%). A systematic review was conducted in PubMed and Scopus from inception to May 2022 to review mechanisms of resistance, prevalence of heteroresistance, and in vivo emergence of resistance to cefiderocol during treatment. A variety of mechanisms, typically acting in concert, have been reported to confer resistance to cefiderocol: β-lactamases (especially NDM, KPC and AmpC variants conferring resistance to ceftazidime/avibactam, OXA-427, and PER- and SHV-type ESBLs), porin mutations, and mutations affecting siderophore receptors, efflux pumps, and target (PBP-3) modifications. Coexpression of multiple β-lactamases, often in combination with permeability defects, appears to be the main mechanism of resistance. Heteroresistance is highly prevalent (especially in A. baumannii), but its clinical impact is unclear, considering that in vivo emergence of resistance appears to be low in clinical studies. Nevertheless, cases of in vivo emerging cefiderocol resistance are increasingly being reported. Continued surveillance of cefiderocol’s activity is important as this agent is introduced in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Bassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y., Ferrer, R., Lodise, T. P., Naas, T., Niki, Y., Paterson, D. L., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30796-9 · Cited by 828
Mechanisms and clinical relevance of bacterial heteroresistance
Andersson, D. I., Nicoloff, H., & Hjort, K. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0218-1 · Cited by 513
Antimicrobial heteroresistance: An emerging field in need of clarity
El-Halfawy, O. M., & Valvano, M. A. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-14 · Cited by 489
Wunderink, R. G., Matsunaga, Y., Ariyasu, M., Clevenbergh, P., Echols, R., Kaye, K. S., Kollef, M., Menon, A., Pogue, J. M., Shorr, A. F., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30731-3 · Cited by 475
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Sato, T., & Yamawaki, K. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz826 · Cited by 379
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-17 · Cited by 202
Kazmierczak, K. M., Tsuji, M., Wise, M. G., Hackel, M., Yamano, Y., Echols, R., & Sahm, D. F. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.10.007 · Cited by 193
Falcone, M., Tiseo, G., Leonildi, A., Della Sala, L., Vecchione, A., Barnini, S., Farcomeni, A., & Menichetti, F. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02142-21 · Cited by 190
Cited by
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens
Saxena, D., Maitra, R., Bormon, R., Czekanska, M., Meiers, J., Titz, A., Verma, S., & Chopra, S. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00016-1 · Cited by 217
Mezcord, V., Escalante, J., Nishimura, B., Traglia, G. M., Sharma, R., Valle, Q., Tuttobene, M. R., Subils, T., Marin, I., Pasterán, F., et al. (2023) · doi:10.20944/preprints202306.0950.v1 · Cited by 27
Metadata
- Authors
- Karakonstantis, S., Rousaki, M., & Kritsotakis, E. I.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2022-05-27
- Volume
- 11
- Issue
- 6
- Pages
- 723
- ISSN
- 2079-6382 (ISSN-L)
- OpenAlex
- W4281923974
- Cited by
- 284
- References
- 64
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. https://app.cochat.ai/papers/10.3390/antibiotics11060723
- The paper
- Karakonstantis, S., Rousaki, M., & Kritsotakis, E. I. (2022). Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics. https://doi.org/10.3390/antibiotics11060723
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
